In hemodynamically stable patients with acute intermediate‑risk pulmonary embolism, how many out of 100 are expected to experience clinical deterioration?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Clinical Deterioration Rate in Intermediate-Risk Pulmonary Embolism

Approximately 9-10 patients out of 100 with hemodynamically stable intermediate-risk pulmonary embolism will experience clinical deterioration, though this varies significantly based on specific risk factors present at admission.

Evidence-Based Deterioration Rates

The most recent guideline data from the 2026 AHA/ACC/ACCP guidelines indicates that 8.8% of intermediate-high risk PE patients experienced clinical deterioration within 48 hours in the Italian Pulmonary Embolism Registry 1. This aligns closely with research showing deterioration rates of 10.5% in a large prospective study of 370 intermediate-risk patients 2.

However, the overall intermediate-risk category encompasses a wide spectrum:

  • Intermediate-high risk patients: 9-15% deterioration rate 3, 4
  • Intermediate-low risk patients: Substantially lower rates (not well-defined in provided evidence)
  • Selected high-risk subgroups: Up to 24% complicated course 4

Critical Time Window

The first 24-72 hours represent the highest risk period for deterioration 1. In the PEITHO trial, hemodynamic collapse occurred at a mean of 1.5-1.79 days after diagnosis 1. This narrow window demands intensive monitoring during the initial hospitalization phase.

Key Risk Stratifiers That Modify This Baseline Risk

Mean Arterial Pressure (MAP)

  • MAP >80 mmHg: Only 2.3% risk of deterioration (negative predictive value 97.7%) 1, 3
  • MAP ≤81.5 mmHg: 3.25-fold increased risk of 48-hour deterioration 3

This is perhaps the most clinically useful bedside parameter—patients with MAP >80 mmHg have an exceptionally low deterioration risk.

Cardiac Index and Normotensive Shock

  • 34% of intermediate-risk patients have isolated hypoperfusion without hypotension (normotensive shock) 1
  • These patients represent a higher-risk subset within the intermediate category

Echocardiographic Parameters

  • Low stroke volume (MOD <36 mL vs. 50 mL in stable patients) strongly predicts deterioration with OR 0.72 2
  • TAPSE <1.54 cm versus 1.81 cm in stable patients 2
  • Worsening TAPSE on repeat echo increases 30-day mortality risk 5.26-fold 5

Clinical Markers

  • Syncope at presentation: 2.8-fold increased risk 6
  • Heart rate normalization within 48 hours: Only 1.4% subsequent deterioration risk 4
  • SaO2 <90%: 5.3-fold increased risk 7

Practical Risk Stratification Algorithm

For a patient with intermediate-risk PE, assess:

  1. MAP at admission

    • If >80 mmHg → ~2-3% deterioration risk (very low)
    • If ≤81.5 mmHg → proceed to step 2
  2. Clinical presentation

    • Syncope present → 12-fold increased risk 7
    • Heart rate >110 bpm → higher risk
    • SaO2 <90% → 5-fold increased risk 7
  3. Echocardiographic findings

    • Stroke volume <40 mL → high risk 2
    • Severe RV dysfunction → 3.5-fold increased risk 6
    • Consider repeat echo at 24-48 hours if initially borderline
  4. Biomarker trajectory

    • Persistently elevated NT-proBNP/troponin at 24-48 hours → higher risk 8
    • Normalization suggests lower subsequent risk

Common Pitfalls

  • Don't rely on single time-point assessment: Serial evaluation within the first 48-72 hours is critical, as deterioration patterns emerge over time 1, 5
  • Don't assume all "intermediate-risk" patients are equivalent: The range spans from 2% to 24% deterioration risk depending on specific parameters 1, 4
  • Don't overlook normotensive shock: One-third of intermediate-risk patients have hypoperfusion despite normal blood pressure 1

Bottom Line

While the textbook answer is approximately 10 out of 100, the actual risk for any individual patient ranges from as low as 2% (MAP >80 mmHg, normalizing vital signs) to as high as 24% (multiple adverse features present) 1, 3, 4. MAP >80 mmHg is the single most powerful reassuring finding, with a negative predictive value of 97.7% 1, 3.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.